Hereditary Pheochromocytoma Assessment of Tumour Immunologies
Launched by RADBOUD UNIVERSITY MEDICAL CENTER · May 30, 2024
Trial Information
Current as of February 12, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how the immune system relates to two types of tumors called pheochromocytomas and paragangliomas, which can be hereditary (passed down in families). The researchers want to understand how the immune system behaves differently in people who have these tumors due to genetic factors compared to those who don’t. They will also look at how the immune system changes as the tumor develops in those with a hereditary predisposition. By comparing these findings with a group of people who don’t have these tumors, the researchers hope to discover new treatments that target the immune system.
To participate in this trial, you need to be at least 18 years old and either newly diagnosed with pheochromocytoma or paraganglioma, or have a genetic mutation that increases your risk for developing these tumors. Participants will be asked to share information about their health and may undergo tests to help researchers learn more about the immune system’s role in these conditions. It’s important to note that if you are currently pregnant, breastfeeding, or have certain other health issues, you may not be eligible for this study. Overall, the goal is to gain valuable insights that could lead to better treatments for these tumors.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Part I:
- • Newly diagnosed patients with PPGL or newly diagnosed patients with (metastatic) PPGL recurrence.
- • OR patients with mutations which predispose for the development of PPGL.
- • Aged \> 18 years.
- Part II:
- • Confirmed PPGL on pathology.
- • Aged \> 18 years.
- Exclusion Criteria:
- • Unable to provide informed consent.
- • Active inflammatory or infectious comorbidities.
- • Other malignancies which are under active treatment (except for basal cell carcinoma, other in situ carcinomas).
- • Using medication interfering with the immune system
- • Pregnancy or breastfeeding
- • A self-reported alcohol consumption of \>21 units per week
Trial Officials
Margo Dona, PhD
Principal Investigator
Radboud University Medical Center
Henri Timmers, M.D. PhD
Principal Investigator
Radboud University Medical Center
Romana Netea-Maier, M.D. PhD
Principal Investigator
Radboud University Medical Center
Marieke de Laat, M.D. PhD
Principal Investigator
Radboud University Medical Center
About Radboud University Medical Center
Radboud University Medical Center is a leading academic medical institution located in Nijmegen, the Netherlands, dedicated to advancing healthcare through innovative research and education. As a prominent sponsor of clinical trials, Radboud UMC leverages its multidisciplinary expertise to conduct high-quality research that aims to improve patient outcomes and enhance medical knowledge. The center is committed to ethical standards and regulatory compliance, fostering collaboration among researchers, healthcare professionals, and patients to translate scientific discoveries into effective clinical applications. With a focus on personalized medicine and cutting-edge technologies, Radboud University Medical Center plays a pivotal role in shaping the future of healthcare through its rigorous clinical trial initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nijmegen, Gelderland, Netherlands
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0